stockportfolio.pro
Rhythm Pharmaceuticals, Inc. (RYTM)
Healthcare · Biotechnology · NasdaqGM
Rhythm Pharmaceuticals, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $3.15M | $23.64M | $77.43M | $130.13M | $189.76M |
| Gross profit | — | — | — | — | — | $2.56M | $21.50M | $68.13M | $116.76M | $170.26M |
| Net income | $-25.87M | $-33.71M | $-74.06M | $-140.73M | $-134.00M | $-69.61M | $-181.12M | $-184.68M | $-260.60M | $-196.54M |
| Net margin | — | — | — | — | — | -2207.1% | -766.2% | -238.5% | -200.3% | -103.6% |
Source: Rhythm Pharmaceuticals, Inc. SEC filings (10-K). 11 years of history available in the interactive view.
Explore 11 years of Rhythm Pharmaceuticals, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track RYTM in your portfolio →
Rhythm Pharmaceuticals, Inc. financial history by metric
About Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Rhythm Pharmaceuticals, Inc. — frequently asked questions
What is Rhythm Pharmaceuticals, Inc.'s revenue?
Rhythm Pharmaceuticals, Inc. (RYTM) reported revenue of $189.76M for fiscal year 2025, up 45.8% from the prior year, according to its SEC filings.
Is Rhythm Pharmaceuticals, Inc. profitable?
No — RYTM reported a net loss of $-196.54M in fiscal 2025.
What is RYTM's P/E ratio?
Rhythm Pharmaceuticals, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Rhythm Pharmaceuticals, Inc. have?
As of fiscal year 2025, RYTM carried roughly $100.89M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Rhythm Pharmaceuticals, Inc.'s gross margin?
RYTM's gross margin was 89.7% in fiscal 2025 — gross profit of $170.26M on revenue of $189.76M.
What is Rhythm Pharmaceuticals, Inc.'s market cap?
Rhythm Pharmaceuticals, Inc. (RYTM) has a market capitalization of about $5.94B, based on the latest data in our nightly-refreshed cache.
When does Rhythm Pharmaceuticals, Inc.'s fiscal year end?
RYTM's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Rhythm Pharmaceuticals, Inc.'s official SEC filings (10-K and 10-Q), covering 11 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.